The article evaluates the long-term follow-up results of PSE using Bletilla striata (BS) particles for @entity6118 in @entity82 , as compared to PSE using gelfoam particles. Fifty-nine @entity1 with @entity82 -induced @entity6118 were treated with PSE. The @entity1 were randomly assigned into two groups: gelfoam group, which includes 32 @entity1 using gelfoam particles as the embolic material, and BS group, which includes 27 @entity1 using BS particles. The peripheral blood cell counts and parameters for complications associated with PSE were measured during the follow-up. The mean values of leukocyte and thrombocyte, but not hemoglobin, were significantly increased after PSE (p < 0.01) in both groups. The values of leukocyte and thrombocyte during the long-term follow-up were significantly improved in BS group than that in gelfoam group (both p < 0.01). The frequency of @entity548 episodes from esophageal varices in both groups was significantly reduced after PSE (both p < 0.01), but the post-PSE @entity548 episodes showed no remarkable differences between the two groups (p = 0.084). @entity887 consisted mainly of fever, @entity390 and @entity391 , and @entity490 in the two groups. The incidence of @entity490 in BS group (82.8%, 27/33) was significantly higher than in gelfoam group (57.9%, 33/57) (p = 0.020). The mean survival time was 61.5    9.1 (median 60, 1-157) months in gelfoam group and 63.4    9.9 (median 52, 0-161) months in BS group, which showed no significant difference (p = 0.930). In conclusion, BS particles could be used as the embolic material in PSE. Compared to gelfoam used in PSE, BS can achieve even better efficacy in alleviating @entity6118 . It provides a long-term effect on the hematological parameters, @entity548 from esophageal varices and good palliation, and improved clinical status contributing to symptomatic control.

Partial splenic embolization using Bletilla striata particles for XXXX in @entity82 : a prospective study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity887 :: ('MESH:D004617', 'Disease') :: ['Post-embolization syndrome'] @entity490 :: ('MESH:D015746', 'Disease') :: ['grade II to III abdominal pain', 'abdominal pain'] @entity6118 :: ('MESH:D006971', 'Disease') :: ['hypersplenism']
@entity6118 :: (MESH:D006971,Disease) :: ['hypersplenism']
